The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Community Fast Track, 2006Study of the Role of Phosphorylation at Ser 129 in Alpha-synuclein Induced Dopaminergic Neurodegeneration in a Rodent Model of Parkinson's Disease
The involvement of alpha-synuclein in Parkinson's disease neurodegeneration is now widely accepted. However, factors and events contributing to the alpha-synuclein toxicity are still being...
-
Community Fast Track, 2006CDNF a novel conserved neurotrophic factor that protects midbrain dopaminergic neurons in vivo
Neuroprotective or neurorestorative therapies for Parkinson's disease are still evolving. We have identified a novel conserved dopamine neurotrophic factor (CDNF) protein which might be beneficial for...
-
Community Fast Track, 2006Specific Intracellular Targeting of Oligomeric Alpha-synuclein as a Potential Therapeutic for Parkinson's Disease
The protein alpha-synuclein is a major constituent of the Lewy Body aggregates that are a hallmark feature of Parkinson's disease. Several genetic studies have also correlated aggregation of alpha...
-
Community Fast Track, 2006Roles of Parkin/PINK1/DJ-1 Complex in Parkinson's Disease Pathogenesis
Mutations in at least six genes, including alpha-synuclein, uchL1, LRRK2, parkin, PINK1, and DJ-1, are linked to Parkinson's disease. One vital question is how mutations in six different genes...
-
Therapeutics Development Initiative, 2006Small molecule TNF-alpha inhibitors as neuroprotectant drugs for PD
Several preclinical and clinical studies implicate the neuroinflammatory cytokine TNF-alpha as a key mediator in PD-associated neurodegenerative pathology. P2D, Inc. has recently identified four lead...
-
Therapeutics Development Initiative, 2006Development of a biodegradable delivery matrix containing dopaminergic neurons derived from clinical grade mesencephalic stem cell lines for the treatment of Parkinson’s disease
The movement disorder seen in Parkinson's disease arises from the loss of dopamine-producing, or dopaminergic, neurons. Regenerative medicine using stem cell therapy provides renewed hope for patients...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.